Multicenter Tissue Registry in Melanoma

Sex: All

Ages: 18 Years – N/A

Enrollment: 1000

Sponsor: Dermatologic Cooperative Oncology Group

Summary

The prospective multicenter translational study Tissue Registry in Melanoma (ADOREG/TRIM; CA209-578) aimed to validate the Tumor Mutational Burden (TMB) and the PD-L1 expression (PD-L1) from a pre-therapeutically obtained tumor tissue sample as a predictor of a subsequent systemic therapy in a large real-world cohort of metastatic melanoma patients.

Eligibility Criteria

Inclusion Criteria:Patients with histologically confirmed melanoma stage III or IV.Clinically eligible for systemic cancer therapy (immune checkpoint inhibitors, targeted agents).Tumor tissue biopsy already existing (metastasis tissue as recent as possible, but older tissue material or primary tumor tissue also possible).Patient has given written informed consent for the current study as well as for his data to be entered into the ADOREG online database system.Patient is ≥18 years old.Exclusion Criteria:-

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05750511). StuddyBuddy aggregates publicly available trial information.